H. Lundbeck A/S- (NASDAQ:HLUYY) has been assigned an average broker rating score of 3.00 (Hold) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.
Zacks has also given H. Lundbeck A/S- an industry rank of 94 out of 265 based on the ratings given to related companies.
HLUYY has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of H. Lundbeck A/S- from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Deutsche Bank AG lowered shares of H. Lundbeck A/S- from a “hold” rating to a “sell” rating in a research note on Friday, July 28th.
Shares of H. Lundbeck A/S- (NASDAQ HLUYY) traded up 1.32% during midday trading on Wednesday, hitting $64.66. 869 shares of the stock were exchanged. The stock has a market cap of $12.76 billion and a P/E ratio of 40.74. H. Lundbeck A/S- has a one year low of $31.00 and a one year high of $64.97. The stock’s 50-day moving average price is $60.39 and its 200 day moving average price is $52.09.
TRADEMARK VIOLATION WARNING: This news story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://ledgergazette.com/2017/09/17/h-lundbeck-as-hluyy-receives-average-recommendation-of-hold-from-analysts.html.
About H. Lundbeck A/S-
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.